How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,317 results for

Instilling Eye Drops

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Data on the effects of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds on intraocular pressure of ocular normotensive rats Full Text available with Trip Pro

Data on the effects of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds on intraocular pressure of ocular normotensive rats This data is to document the intraocular pressure (IOP) lowering activity of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds in ocular normotensive rats. Effects of single drop application of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds on IOP in ocular normotensive rats are presented at 3 different (...) concentrations (0.1%, 0.2% and 0.4%). Time course of changes in IOP is presented over 6 h period post-instillation. The IOP lowering activities of test compounds were determined by assessing maximum decrease in IOP from baseline and corresponding control, duration of IOP lowering and area under curve (AUC) of time versus response curve. Data shown here may serve as benchmarks for other researchers studying IOP-lowering effect of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds and would

2018 Data in brief

162. Anterior Corneal Folds Correlate with Low Intraocular Pressure and May Serve as a Marker for Ocular Hypotony. (Abstract)

after instilling an anesthetic drop and fluorescein staining. Outcome measures included: IOP, presence of anterior corneal folds, and the percentage of corneal surface containing folds.Overall, 100 eyes of 100 patients were included. The mean age±SD was 63.6±16.7 years (range, 19 to 96 y); 56% (n=56) were of male sex. Mean IOP was 5.3±2.7 mm Hg (range, 0 to 9 mm Hg). Subjects with and without anterior corneal folds were of similar age (P=0.25) and sex (P=0.69). Those with anterior corneal folds had (...) Anterior Corneal Folds Correlate with Low Intraocular Pressure and May Serve as a Marker for Ocular Hypotony. Subtle folds can be seen in the anterior cornea in eyes with hypotony using fluorescein and blue light. We aim to assess their extent and grade with respect to the level of intraocular pressure (IOP).Patients who presented to the department of ophthalmology at Rambam Health Care Campus with IOP<10 mm Hg during the period between July 2016 and June 2017. Corneal folds were evaluated

2018 Journal of Glaucoma

163. Effect of prophylactic antibiotic drops on ocular microbiota and physiology during silicone hydrogel lens wear. (Abstract)

% (test) or saline (control) drop group. Two drops were instilled into each eye on waking and before sleep. At monthly visits, lenses were collected aseptically, and ocular and throat swabs were performed, followed by standard microbial recovery and identifications. Any corneal infiltrative event at scheduled or unscheduled visits was recorded.Numbers of microbes recovered from eye swabs from the tobramycin (test) group were significantly lower than the control (p = 0.01). Gram-positive cocci were (...) Effect of prophylactic antibiotic drops on ocular microbiota and physiology during silicone hydrogel lens wear. Bacterial contamination of the contact lens surface has been demonstrated to cause corneal infiltrative events. A reduction in the rate of bacterially driven corneal infiltrative events associated with lens wear is one of the major goals of the contact lens industry. There is a concern over the potential of any antimicrobial strategy that there will be unwanted changes to the ocular

2012 Optometry and vision science : official publication of the American Academy of Optometry Controlled trial quality: uncertain

164. A Pilot Study: The Efficacy of Virgin Coconut Oil as Ocular Rewetting Agent on Rabbit Eyes Full Text available with Trip Pro

A Pilot Study: The Efficacy of Virgin Coconut Oil as Ocular Rewetting Agent on Rabbit Eyes Purpose. An open-label pilot study of virgin coconut oil (VCO) was conducted to determine the safety of the agent as ocular rewetting eye drops on rabbits. Methods. Efficacy of the VCO was assessed by measuring NIBUT, anterior eye assessment, corneal staining, pH, and Schirmer value before instillation and at 30 min, 60 min, and two weeks after instillation. Friedman test was used to analyse any changes (...) (P > 0.05). Conclusion. VCO acts as safe rewetting eye drops as it has shown no significant difference in the measurable parameter compared to commercial brand eye drops and saline. These study data suggest that VCO is safe to be used as ocular rewetting agent on human being.

2015 Evidence-based Complementary and Alternative Medicine : eCAM

165. Dry Eye

Contacts) Consider eye lubricants (e.g. lacrilube) for moderate symptoms (esp. at night), but may blur vision Avoid agents with (e.g. Visine original) Consider s and other agents in refractory to other measures (Restasis) ( ) ( ) Other options in refractory cases Lifitegrast (Xiidra) function-associated antigen-1 (LFA-1) antagonist ophthalmic solution One drop instilled every 12 hours Expensive (>$400/month), with risk of eye irritation, altered es must be out of eye for installation for at least 15 (...) . Epidemiology As many as 30% of over age 50 years old complain of dry, irritated eyes III. Causes Decreased blinking with prolonged reading or driving Chronic exposure to dry, dusty conditions See (e.g. s, s, ) IV. Management ral measures Room humidifiers Take computer breaks Protect eyes from fan Avoid drying, s ( s, s, s) Artificial tears or ointments Preservative-free solutions are preferred (e.g. Refresh Plus), esp. if used more than 4x/day users may try rewetting drops (e.g. Renu rewetting, Blink

2017 FP Notebook

166. Glaucoma Eye Drop Instillation: Impact of Education

ophthalmologist for at least 6 months Diagnosis of open-angle glaucoma or ocular hypertension The use of one, two or three self-instilled eye drop medications in one or two eyes Age 40-85 years Fluency in English Best corrected visual acuity (BCVA) of 20/50 or better in each eye Exclusion Criteria: Presence of moderate to severe cognitive deficits Presence of a clinically significant tremor Mini Mental Status Exam score ≤ 20 Contacts and Locations Go to Information from the National Library of Medicine (...) Glaucoma Eye Drop Instillation: Impact of Education Glaucoma Eye Drop Instillation: Impact of Education - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Glaucoma Eye Drop Instillation: Impact of Education

2011 Clinical Trials

167. Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma

Oftalmológico de Alicante Information provided by (Responsible Party): Vissum, Instituto Oftalmológico de Alicante Study Details Study Description Go to Brief Summary: To evaluate the efficacy of autologous platelet-rich plasma eye drops (E-PRP) for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK). Condition or disease Intervention/treatment Phase Dry Eye After LASIK-Laser in Situ Keratomileusis Biological: PRP autologous Phase 2 Detailed Description (...) ). On this modified scale, the score 0 corresponds to no staining dots and the score 0.5 to three or less staining dots. A CFS grade of 0 represents complete corneal clearing. A negative change from baseline will indicate improvement. Secondary Outcome Measures : Dry eye symptoms [ Time Frame: Before LASIK surgery and after the 6 weeks of treatment ] The symptoms of ocular discomfort (unrelated to instillation of the study medication), burning/stinging, foreign body sensation, eye dryness, pain, will be assessed

2017 Clinical Trials

168. Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits Full Text available with Trip Pro

in rabbits. We also studied the IOP changes when 0.4% ripasudil was combined with 2% pilocarpine, 0.5% timolol or 0.1% dorzolamide.One drop of saline solution, 0.4% ripasudil, 0.5% timolol, 2% pilocarpine or 1% dorzolamide or a combination of these agents was applied topically to the left eyes of eight healthy albino rabbits. Posttreatment changes in the IOP of albino rabbits were monitored using a rebound tonometer over a 5-h time course. Changes in IOP after application of saline served as the control (...) Ocular hypotensive effects of a Rho-associated protein kinase inhibitor in rabbits Ripasudil is a novel Rho-associated protein kinase inhibitor that is used to treat ocular hypertension. However, the comparison of the intraocular pressure (IOP)-lowering effects between ripasudil alone and other ocular hypotensive drugs has not been studied thoroughly. The purpose of this study is to examine the ocular hypotensive effects of 0.4% ripasudil, 2% pilocarpine, 0.5% timolol and 0.1% dorzolamide

2017 Clinical ophthalmology (Auckland, N.Z.)

169. Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of LE Ophthalmic Gel Actual Study Start Date : April 10, 2017 Actual Primary Completion Date : May 12, 2017 Actual Study Completion Date : May 12, 2017 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Loteprednol Etabonate Ophthalmic Gel one drop per eye for each eye Drug: Loteprednol Etabonate one drop per eye for each eye (...) Update Posted : May 18, 2017 Sponsor: Bausch & Lomb Incorporated Information provided by (Responsible Party): Bausch & Lomb Incorporated Study Details Study Description Go to Brief Summary: Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel Condition or disease Intervention/treatment Phase Healthy Drug: Loteprednol Etabonate Phase 1 Detailed Description: This will be a single-center, single-arm, open

2017 Clinical Trials

170. Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

: a multicentric, prospective, crossover (2x2), double blind clinical study. Sample size: one hundred patients with primary open angle glaucoma or ocular hypertension. Patients in the period 1: In the first sequence 60 patients will be assigned to receive the ophthalmic solution: Krytantek Ofteno ® (timolol 0.5%%/brimonidine 0.2%/dorzolamide 2%) 1 drop B.I.D. during 30 days and the second sequence 60 patients will be assigned to receive the ophthalmic solution: PRO-122 1 drop B.I.D. during 30 days in the same (...) B.I.D. into the lower conjunctival sac of either formulations and were examined at days: 1, 15, 30, 45 and 61 after initiation of treatment. A phone call security at day 75 will be performed. Primary efficacy outcome: To evaluate the efficacy of PRO-122 versus Krytantek Ofteno® instilled onto the ocular surface in subjects with primary open angle glaucoma (POAG) or ocular hypertension (HTO), to control and maintenance of the target intraocular pressure (TIOP). Study Design Go to Layout table

2017 Clinical Trials

171. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Full Text available with Trip Pro

Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. The SANSIKA study was conducted to assess the treatment effect of 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops on signs and symptoms of patients with severe dry eye disease (DED).This was a multicenter, randomized, double-masked, 2-parallel-arm, 6-month phase III study with a 6-month open-label treatment safety follow-up. Patients with severe DED (...) CFS change from baseline to month 6 (-1.764 vs -1.418, p = 0.037). There was a reduction in ocular surface inflammation assessed by human leukocyte antigen DR expression in favor of CsA CE at month 6 (p = 0.021). The mean OSDI change from baseline was -13.6 with CsA CE and -14.1 with vehicle at month 6 (p = 0.858). The main adverse event was instillation site pain (29.2% vs 8.9% in the CsA CE and vehicle groups, respectively), and it was mostly mild.CsA CE was well-tolerated and effective

2016 European journal of ophthalmology Controlled trial quality: uncertain

172. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Full Text available with Trip Pro

test score ≥1 and ≤10 mm; corneal staining score ≥2.0) were randomized 2:1 to lifitegrast ophthalmic solution 5.0% or placebo twice daily for 360 days. The primary objective was percentage and severity of treatment-emergent adverse events (TEAEs). Secondary objectives were ocular safety measures: corneal fluorescein staining, drop comfort, best-corrected visual acuity, slit-lamp biomicroscopy, and intraocular pressure over 7 visits. Exploratory objectives included concentration of lifitegrast (...) in plasma.The safety population comprised 331 participants (220 lifitegrast; 111 placebo). There were no serious ocular TEAEs. Overall, 53.6% of participants receiving lifitegrast experienced ≥1 ocular TEAE versus 34.2% in the placebo group; most TEAEs were mild to moderate in severity. Rates of discontinuation because of TEAEs were 12.3% (lifitegrast) versus 9.0% (placebo). The most common (>5%) TEAEs occurring in either treatment group were instillation site irritation (burning), instillation site

2016 Cornea Controlled trial quality: predicted high

173. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. Full Text available with Trip Pro

Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. The purpose of this study is to assess the effectiveness and tolerability of a dietary supplement with a combination of omega-3 fatty acids and antioxidants on dry eye symptoms caused by chronic instillation of antihypertensive eye drops in patients with glaucoma.A total of 1,255 patients with glaucoma and dry eye symptoms related to antiglaucoma topical medication (...) eye symptoms were statistically significant as compared to noncompliant patients.Dietary supplementation with Brudypio(®) may be a clinically valuable additional option for the treatment of dry eye syndrome in patients with glaucoma using antiglaucoma eye drops. These results require confirmation with an appropriately designed randomized controlled study.

2016 Clinical ophthalmology (Auckland, N.Z.)

174. Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

with moderate to severe dry eye (tear osmolarity > 320 mOsm/L and Visual Analog Scale (VAS) score > 40), willing to adhere to twice daily dosing (BID) and follow up visit schedule, have no history of ocular pathology / degeneration / allergy, not on any T-cell modulatory therapy, not have instilled any artificial tears within 2 hours of study visit, and not participating in any concurrent clinical trials. All subjects will complete an informed consent form indicating their voluntary participation (...) Study Details Study Description Go to Brief Summary: To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months. Condition or disease Intervention/treatment Phase Dry Eye Drug: Lifitegrast Phase 4 Detailed Description: A longitudinal, single-arm, prospective study will recruit up to 30 subjects with moderate to severe dry eye disease. Subjects will be >18 years of age, diagnosed

2016 Clinical Trials

175. The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model Full Text available with Trip Pro

treatment. Preservative-free eye drops were instilled in the positive-control group. The tear secretion volume (Schirmer's test), tear break-up time (BUT), and fluorescein score were measured on the ocular surface. BAC-induced corneal damage was tested with hematoxylin-eosin staining. Moreover, apoptotic cell death in the corneal epithelial layer was investigated with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The protein expression level of interleukin (...) The leaves of Diospyros kaki exert beneficial effects on a benzalkonium chloride–induced murine dry eye model In this study, the beneficial effects of the oral administration of ethanol extract of Diospyros kaki (EEDK) were tested on a mouse dry eye model induced by benzalkonium chloride (BAC).A solution of 0.2% BAC was administered topically to mouse eyes for 14 days, twice daily, to induce dry eye. Various concentrations of EEDK were administrated daily by oral gavage for 14 days after BAC

2016 Molecular vision

176. Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements. Drug: Phenylephrine 2.5% Instilling phenylephrine 2.5% eye drop Outcome Measures Go to Primary Outcome Measures : Change in episcleral venous pressure [ Time Frame: baseline, 60 minutes ] Comparison using a two-sided t-test Secondary Outcome Measures : Change in intraocular pressure [ Time Frame: baseline, 60 minutes ] Comparison using a two-sided t-test Eligibility Criteria Go to Information (...) ., Mayo Clinic Study Details Study Description Go to Brief Summary: Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris. Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non

2016 Clinical Trials

177. Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Intervention/treatment Experimental: AGN-195263 Drug: AGN-195263 1 drop of AGN-195263 will be instilled in each eye twice daily. Placebo Comparator: Vehicle Drug: Vehicle 1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily. Outcome Measures Go to Primary Outcome Measures : Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe) [ Time Frame: 6 month visit ] The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1 (...) ), omega-3 supplementation (topical ocular or systemic), or antibiotics (ie, systemic or topical macrolides, tetracyclines, tetracycline derivatives [including doxycycline and minocycline]) for the treatment of dry eye disease, or meibomian gland disease within 1 year of the standardization (day -21) visit Exclusion Criteria: Male patients with a history of, known, or suspected prostate cancer Male patients with a prostate-specific antigen (PSA) level ≥ 4 μg/L Female patients with a history of known

2016 Clinical Trials

178. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

for the Treatment of Dry Eye : ARISE-2 Actual Study Start Date : November 2016 Actual Primary Completion Date : September 2017 Actual Study Completion Date : March 2018 Arms and Interventions Go to Arm Intervention/treatment Experimental: RGN-259 RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4 Drug: RGN-259 A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days Other Names: Tβ4 Thymosin Beta 4 Placebo (...) reported history of dry eye for at least 6 months Have a history of use or desire to use eye drops for dry eye symptoms within 6 months Exclusion Criteria: Have any clinically significant slit-lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies that require therapeutic treatment, and/or in the opinion of the investigator may interfere with study parameters; Be diagnosed with an ongoing ocular infection

2016 Clinical Trials

179. Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome

is usually reached by the use of artificial tears during the day. Nighttime relief is often achieved by substances known to be more adhesive to the ocular surface, such as gels. Condition or disease Intervention/treatment Phase Dry Eye Syndromes Device: Thealoz Duo eye drops and Thealoz Duo gel Device: Thealoz Duo gel Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Allocation: Randomized Intervention (...) during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days Other Name: Intervention 1 Device: Thealoz Duo gel Thealoz Duo gel during the day and at night for 7 days Other Name: Intervention 2 Outcome Measures Go to Primary Outcome Measures : Number of drops of Thealoz Duo® eye drops and Thealoz Duo® gel instilled during the day (patient diary) [ Time Frame: 4 weeks ] Number of drops of Thealoz Duo® eye drops and Thealoz Duo® gel instilled during the day during the observation

2016 Clinical Trials

180. Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome

and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Dry Eye Symptoms (SPEED Questionnaire) [ Time Frame: Day 0 ] Secondary Outcome Measures : Non-invasive Tear Break-up Time (NIKBUT) [ Time Frame: Day 0 ] Conjunctival Redness Grading with Oculus Keratograph 5M [ Time Frame: Day 0 ] Tear collection from Schirmers strip [ Time Frame: Day 0 ] To profile immune cells with EyePRIM membrane [ Time Frame: Day 0 ] Patients will be instilled with 1 drop of local anaesthetic. Conjunctival cells (...) : Singapore National Eye Centre Collaborators: SingHealth Translational Immunology and Inflammation Centre TTSH Eye Clinic Information provided by (Responsible Party): Louis Tong, Singapore National Eye Centre Study Details Study Description Go to Brief Summary: Ocular surface disease, especially dry eye and scleritis, commonly affects patients with autoimmune diseases. Ocular surface immune cells are increased in autoimmune disease; however the full subset of immune cells activated is unknown. Recent

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>